"wray" <wk.ephart@ya.hoo.com> wrote in news:1150j9b65845206
@corp.supernews.com:

ask me in a week, or share off froup responses here

A search turned up a British study that showed no change in longevity but
substantial improvements in quality of life.

Vinorelbine (Navelbine)
breast cancer newsgroup
http://tinyurl.com/5tzha
http://groups-beta.google.com/groups/abuse?group=alt.support.cancer&url=http:%2F
%2Fgroups-beta.google.com%2Fgroup%2Falt.support.cancer%2Fmsg%2F0762f8a66acca6bf

BestTreatments :: Conditions :: Lung cancer :: Evidence
... People who had both gemcitabine and vinorelbine (Navelbine) typically
lived
for 29 weeks, compared with 18 weeks for those who just had vinorelbine.
...
www.besttreatments.co.uk/btuk/conditions/7600.html -
Alf? could you look at & copy paste the above here, only those in UK can
access.

Does this say "less toxicity combined than given individually"?
http://patient.cancerconsultants.com/lung_cancer_news.aspx?id=18032

http://www.chestjournal.org/cgi/content/full/117/6/1583
(Chest. 2000;117:1583-1589.)
© 2000 American College of Chest Physicians
A Multicenter Phase II Trial of Vinorelbine Plus Gemcitabine in Previously
Untreated Inoperable (Stage IIIB/IV) Non-small Cell Lung Cancer*
Study objective: Vinorelbine and gemcitabine are two active single agents
used in the treatment of non-small cell lung cancer (NSCLC). A clinical
trial was conducted to evaluate the efficacy and toxicity of vinorelbine
plus gemcitabine in patients with inoperable (stage IIIB or IV) NSCLC.

Design: A multicenter phase II study. Vinorelbine, 20 mg/m2, was given as
a 10-min IV infusion, followed by a 30-min IV infusion of gemcitabine, 800
mg/m2, on days 1, 8, and 15 of each 28-day cycle.

Patients and measurements: From March 1998 to August 1998, 40 patients
were enrolled in the study. The efficacy and toxicity of the treatment
were recorded.

Results: All patients are evaluable for treatment response and toxicity
profile. Two patients achieved a complete response, and 27 patients
achieved a partial response, with an overall response rate of 72.5% (95%
confidence interval, 58.7 to 86.3%). Median survival time was 11 months.
The significant (World Health Organization grade, 3/4) toxicities were
myelosuppression, including leukopenia (47.5% of patients), anemia (17.5%
of patients), and thrombocytopenia (12.5% of patients). However, febrile
neutropenia occurred in three patients and accounted for one
treatment-related death. Fatigue, or flu-like syndrome, occurred in 17
patients, and the symptoms were reversed spontaneously 1 to 2 days after
injection in 10 patients. Another seven patients needed dose reduction to
ameliorate symptoms. Interstitial pneumonitis occurred in six patients who
recovered after steroid treatment. No patient suffered from grade 3 or 4
nausea/vomiting.

Conclusion: The combination of vinorelbine and gemcitabine in patients
with advanced NSCLC is a highly active non-cisplatin-containing regimen
with an acceptable toxicity profile.

and ask at ACOR mailing lists..although comparing to someone else, seems
to me previous treatments may vary the side effects/outcome along with
dose of the combo (could vary patient-patient) you are inquiring about,
yes?
J